BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $16
Neurogene Price Target Cut to $16.00/Share From $45.00 by BMO Capital
Neurogene Is Maintained at Outperform by BMO Capital
Neurogene Analyst Ratings
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Neurogene's Promising Clinical Progress and Financial Stability Earns Buy Rating
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $50
Baird Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $38
Neurogene Is Maintained at Buy by HC Wainwright & Co.
Neurogene Analyst Ratings
William Blair Sticks to Its Buy Rating for Neurogene (NGNE)
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $55
Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.